Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol
Recently published Austrian study proved that ceramide-based cardiovascular risk test, CERT2, provides more accurate cardiovascular risk prediction than LDL-C.
Read moreInvitation to the Annual General Meeting
Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Thursday, June 30th, 2022 at 10:00…
Read moreInvitation to the Annual General Meeting
Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Tuesday, September 28th, 2021 at 11:00…
Read moreZora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
Zora Biosciences Oy announced it has signed a license agreement with Quest Diagnostics, the world leader in diagnostic information services, for Zora’s patented ceramide-analysis technology.
Read moreZora is part of major European heart disease prevention project
The project is executed together with European Society of Cardiology, ESC, and National Institute for Health and Care Excellence, NICE, as well as cardiologists throughout the Europe.
Read moreLDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients
New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests
Read moreZora Biosciences Pushing Ceramide Testing to Assess Cardiovascular Risk
Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.
Read moreZora Brings Molecular Lipids to the Clinic for Cardiovascular Risk Prediction with Enhanced Capacity
Zora’s laboratory has been able to improve its robotized mass spectrometry workflow such that one machine is able to analyze up to 12 000 samples per…
Read moreZora participates XXXVI Nordic Congress in Clinical Chemistry -congress in June at Helsinki
Zora participates XXXVI Nordic Congress in Clinical Chemistry in June 12-15, 2018 at Helsinki, Finlandia Hall. Nordic Congress in Clinical Chemistry is notable event in…
Read moreNew Generation Lipid Test: Are Ceramides New Cholesterol?
Scott Summers from University of Utah discusses at Cell Metabolism Journal, could recently introduced ceramide testing become new cholesterol. Zora has developed a ceramide based…
Read morePlasma ceramides highlighted in European Heart Journal
European Heart Journal recently highlighted Zora's invention, new blood test that predicts cardiovascular events in patients with or without coronary artery disease. The test is…
Read moreMayo Clinic will present plasma ceramide results at ACC 2017
The CERAM test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly…
Read moreWhat are plasma ceramides?
Learn what are plasma ceramides and why you should measure your ceramides. Watch Dr. Jeff Meeusen’s informative video on plasma ceramides and their relation to…
Read moreHeart Attack Risk Test, CERT, is available from various medical centers in Finland
Heart Attack Risk Test, CERT, is available from various medical centers in Finland CERT-test measures persons risk of getting a heart attack or even heart-related…
Read moreCoronary Event Risk Test available in Finland through United Medix Laboratories
Ceramides, Coronary Event Risk Test, CERT Coronary Event Risk Test, CERT, is a new diagnostic test for evaluation of risk of heart attack and CVD-related…
Read moreWe are hiring – Join Zora-team
Zora Biosciences is looking for a Bioinformatician Zora Biosciences Oy is a discovery diagnostics company. Zora identifies, validates and develops novel clinical tools using a…
Read morePlasma Ceramide test is now available at Mayo Clinic Medical Laboratories
Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…
Read moreZora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing
Zora and Mayo Medical Laboratories has signed Collaborate on Plasma Ceramides Testing. The test will be launched in summer, and is used to predict adverse…
Read moreZora at EAS 2016 Innsbruck
Zora participates 84th EAS Congress at Innsbruck, Austria. Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at…
Read moreZora at Nature Reviews Research Highlights
Zora's recent publication on CERT was reviewed in Nature Reviews Cardiology Research Highlights. Read the research highlight here.
Read more